Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04122703 · ClinicalTrials.gov registry record · NA

Trial of Tibial Nerve Stimulation for Treating Sexual Dysfunction

A NA study of Female Sexual Dysfunction, sponsored by Stony Brook University.

Completed
Registry status
NA
Development phase
66
Enrollment target
1
Study location

NCT04122703 is a NA study of Female Sexual Dysfunction that has completed, run by Stony Brook University. The registered enrollment target is 66 participants, below the 73-participant average among 4 other Female Sexual Dysfunction trials with a reported enrollment target (10% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04122703, a NA study of Female Sexual Dysfunction, has completed, sponsored by Stony Brook University.

COMPLETED
Registry status
NA
Development phase
66 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to understand the efficacy of PTNS versus a placebo in the treatment of female sexual dysfunction syndrome.

Conditions Studied

Interventions

  • DEVICE percutaneous tibial nerve stimulation (PTNS)
  • DEVICE Sham procedure

Study Locations (1)

New York

  • Stony Brook Medicine Women's Pelvic Health And Continence Center - Stony Brook

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2019-09-15
Est. Completion 2023-06-30
Phase NA

Sponsor

Stony Brook University

127 total trials

What the Registry Record Tells You About NCT04122703

The ClinicalTrials.gov registry entry for NCT04122703 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 73-participant average among 4 other Female Sexual Dysfunction trials with a reported enrollment target (10% lower). The listed sponsor is Stony Brook University, which has 127 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Female Sexual Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which percutaneous tibial nerve stimulation (PTNS) is the first listed.

NCT04122703 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT04122703 about?

NCT04122703 is a clinical study titled "Trial of Tibial Nerve Stimulation for Treating Sexual Dysfunction". The purpose of this study is to understand the efficacy of PTNS versus a placebo in the treatment of female sexual dysfunction syndrome.

What is the current status of trial NCT04122703?

This trial is currently completed. It is a NA study. The enrollment target is 66 participants. The study started on 2019-09-15. Estimated completion is 2023-06-30.

What conditions does trial NCT04122703 study?

This clinical trial studies the following conditions: Female Sexual Dysfunction.

What interventions are being tested in trial NCT04122703?

The interventions under investigation include: percutaneous tibial nerve stimulation (PTNS) (DEVICE), Sham procedure (DEVICE).

Who is sponsoring clinical trial NCT04122703?

This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04122703 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Female Sexual Dysfunction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.